Trial · NCT01719367
Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation
NCT01719367, Not applicable, Completed, Vanderbilt University Medical Center; results first posted 2019-06-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation. Trials, record NCT01719367. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01719367
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation
- NCT number
- NCT01719367
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 38 participants, actual
- Lead sponsor
- Vanderbilt University Medical Center
- Conditions
- Atrial Fibrillation
- Interventions
- Atenolol
- First posted
- 2012-11-01
- Last updated
- 2019-06-17
- Results first posted
- 2019-06-17
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Pre- and Post-atenolol Ventricular Rate Response After 5 Minutes of Exercise | after 5minutes of exercise | After baseline vital signs and ECG are recorded, patients will be asked to perform a baseline standardized (modified Bruce) exercise protocol. Heart rate will be recorded during each stage of the exercise protocol. Patients will be asked to exercise to sub-maximal exertion. After the baseline exercise protocol, patients will be given a single dose of oral atenolol. After a two hour waiting period to allow for peak effect of atenolol, patients will repeat the exercise protocol. The primary study outcome measure will be the difference in pre- and post-atenolol ventricular rate response to exercise. The primary outcome measure will be compared in patients with various polymorphisms in genes that might play a role in the inter-individual response to atenolol. |
| Primary | Change in Pre- and Post-atenolol Ventricular Rate Response After 10 and 15 Minutes of Exercise | after 10 amd 15 minutes of exercise | After baseline vital signs and ECG are recorded, patients will be asked to perform a baseline standardized (modified Bruce) exercise protocol. Heart rate will be recorded during each stage of the exercise protocol. Patients will be asked to exercise to sub-maximal exertion. After the baseline exercise protocol, patients will be given a single dose of oral atenolol. After a two hour waiting period to allow for peak effect of atenolol, patients will repeat the exercise protocol. The primary study outcome measure will be the difference in pre- and post-atenolol ventricular rate response to exercise. The primary outcome measure will be compared in patients with various polymorphisms in genes that might play a role in the inter-individual response to atenolol. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Pre- and Post-atenolol Ventricular Rate Response After 5 Minutes of Exercise | after 5minutes of exercise | beats per minute | MEAN | |
| PRIMARY | Change in Pre- and Post-atenolol Ventricular Rate Response After 10 and 15 Minutes of Exercise | after 10 amd 15 minutes of exercise | beats per minute | MEAN |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Pre- and Post-atenolol Ventricular Rate Response After 5 Minutes of Exercise | Atenolol: Ancestral Alleles | -10 | 95% Confidence Interval -18.6 to -1.4 | beats per minute | |
| Change in Pre- and Post-atenolol Ventricular Rate Response After 5 Minutes of Exercise | Atenolol: Variant Carriers | -13 | 95% Confidence Interval -20.2 to -5.8 | beats per minute | |
| Change in Pre- and Post-atenolol Ventricular Rate Response After 10 and 15 Minutes of Exercise | Atenolol: Ancestral Alleles | After 10 minutes | -11 | 95% Confidence Interval -21.9 to -0.1 | beats per minute |
| Change in Pre- and Post-atenolol Ventricular Rate Response After 10 and 15 Minutes of Exercise | Atenolol: Variant Carriers | After 10 minutes | -19.7 | 95% Confidence Interval -25.6 to -13.9 | beats per minute |
| Change in Pre- and Post-atenolol Ventricular Rate Response After 10 and 15 Minutes of Exercise | Atenolol: Ancestral Alleles | After 15 minutes | -25.5 | 95% Confidence Interval -67 to -16.8 | beats per minute |
| Change in Pre- and Post-atenolol Ventricular Rate Response After 10 and 15 Minutes of Exercise | Atenolol: Variant Carriers | After 15 minutes | -35.2 | 95% Confidence Interval -53.3 to -17.1 | beats per minute |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Atenolol: Ancestral Alleles | 19 | |
| Overall Study | STARTED | Atenolol: Variant Carriers | 19 | |
| Overall Study | COMPLETED | Atenolol: Ancestral Alleles | 19 | |
| Overall Study | COMPLETED | Atenolol: Variant Carriers | 19 | |
| Overall Study | NOT COMPLETED | Atenolol: Ancestral Alleles | 0 | |
| Overall Study | NOT COMPLETED | Atenolol: Variant Carriers | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Atenolol: Ancestral Alleles | 0 | 19 |
| Total, all-cause mortality | Atenolol: Variant Carriers | 0 | 19 |
| Total, other adverse events | Atenolol: Ancestral Alleles | 0 | 19 |
| Total, other adverse events | Atenolol: Variant Carriers | 0 | 19 |
| Total, serious adverse events | Atenolol: Ancestral Alleles | 0 | 19 |
| Total, serious adverse events | Atenolol: Variant Carriers | 0 | 19 |
Source ClinicalTrials.gov
Papers15
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Atenolol: Ancestral Alleles vs Atenolol: Variant Carriers: deaths from any cause | Trial comparisons |
| Atenolol: Ancestral Alleles vs Atenolol: Variant Carriers: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01719367
GET https://conductscience.org/api/trials/v1/NCT01719367/registered